-
-
-
-
-
-
-
FDA approves first PROTAC therapy VEPPANU for breast cancer
-
-
-
-
-
-
-
Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)
-
-
-
-
-
-
-
Truist: 'Potential Impact of Trump's Nominees on Biopharma'
-
-
-
-
-
-
-
Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance
-
-
-
-
-
-
-
Everest Medicines Announces Interim Results for First Half of 2023
-
-
-
-
-
-
-
U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults
-
-
-
-
-
-
-
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™
-
15,694 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

